Cleared Traditional

Uramix CuraWay Biopsy Needle (K203141) - FDA 510(k) Clearance

Class II General & Plastic Surgery device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K203141 · Uramix, Inc. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2021
Decision
332d
Days
Class 2
Risk

K203141 is an FDA 510(k) clearance for the Uramix CuraWay Biopsy Needle. Classified as Instrument, Biopsy (product code KNW), Class II - Special Controls.

Submitted by Uramix, Inc. (Lansdowne, US). The FDA issued a Cleared decision on September 17, 2021 after a review of 332 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 876.1075 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.

View all Uramix, Inc. devices

Submission Details

510(k) Number K203141 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 20, 2020
Decision Date September 17, 2021
Days to Decision 332 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
217d slower than avg
Panel avg: 115d · This submission: 332d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KNW Instrument, Biopsy
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 876.1075
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General & Plastic Surgery devices follow this clearance model.

Regulatory Peers - KNW Instrument, Biopsy

All 105
Devices cleared under the same product code (KNW) and FDA review panel - the closest regulatory comparables to K203141.
TeesuVac Breast Biopsy Device Mark 1
K212079 · Teesuvac Aps · Feb 2022
Arthrex Vortex Threaded Bone Marrow Recovery Needle
K213213 · Arthrex, Inc. · Nov 2021
Disposable Automatic Core Biopsy Instrument
K212284 · Suzhou Leapmed Healthcare Corporation · Nov 2021
Promisemed Automatic Biopsy Needles, Promisemed Co-Axial Biopsy Devices, Promisemed Semi-automatic Biopsy Needles
K210946 · Promisemed Hangzhou Meditech Co., Ltd. · Aug 2021
EleVation Breast Biopsy System
K211933 · Bard Peripheral Vascular · Jul 2021
Avitus(r) Bone Harvester
K210631 · Avitus Orthopaedics, Inc. · Mar 2021